I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

It is known that in patients who experienced acute ST-segment elevation myocardial infarction (STEMI), the acute injury may evolve in the left ventricular remodeling (LVR) despite effective coronary revascularization and optimal medical therapy. Predicting LVR in these patients can be challenging.\[[@ref1]\] Different parameters obtained by cardiac imaging techniques have been proposed over the years,\[[@ref1]\] including LV end-diastolic and end-systolic volumes (EDV, ESV) and ejection fraction (EF) by conventional and three-dimensional echocardiography,\[[@ref2][@ref3]\] global longitudinal strain (GLS) by two-dimensional speckle-tracking echocardiography (2D-STE),\[[@ref4]\] microvascular obstruction (MVO),\[[@ref5]\] and LV global function index (LV-GFI) by cardiac magnetic resonance (CMR) imaging.\[[@ref6]\]

Recently, the size of the myocardial area with severely altered longitudinal strain (SAS) evaluated by 2D-STE has been shown to correlate with the transmural myocardial infarct size.\[[@ref7]\] For this reason, this area has the potential to predict LVR if applied early in the acute phase of STEMI. Therefore, the purpose of this study was to evaluate the value of the LV SAS area in predicting LVR after STEMI and also to compare it with other echocardiographic and CMR predictors of LVR.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Study design {#sec2-1}
------------

We have retrospectively reviewed our Cardiology Unit database looking for all patients accessed consecutively for acute STEMI for 2 years, with CMR performed early and after 6 months. The diagnosis of STEMI was made on the basis of clinical presentation, electrocardiographic findings, and troponin elevation. Study inclusion criteria were (1) no history of cardiovascular disease and no previous coronary revascularization; (2) myocardial revascularization within 90 min from the onset of symptoms with effective coronary flow after revascularization (TIMI III); (3) echocardiography study with dedicated protocol for speckle-tracking analysis between 4 and 7 days after the acute event; (4) CMR within 7 days and after 6 months from the acute event; (5) sinus rhythm at the moment of both CMR and echocardiography. Exclusion criteria were (1) new angiographic procedures within 6 months after the first event; (2) hemodynamic instability or periprocedural MI. Forty-one patients met the inclusion criteria. Patient characteristics are reported in [Table 1](#T1){ref-type="table"}. The main indications for early CMR were detailed functional assessment of both ventricles, characterization of myocardial tissue, and suspect LV thrombus; the main indication for the 6-month CMR was the study of LVR. The study was approved by the local Ethics Committee.

###### 

Patient characteristics

                                      Overall patients   Patients with LVR   Patients without LVR   *P*
  ----------------------------------- ------------------ ------------------- ---------------------- ---------
  *n* (%)                             41 (100)           10 (24)             31 (76)                \<0.001
  Age (years)                         59±10              55.4±9.1            61.2±11.2              0.094
  Sex (male/female)                   36/5               9/1                 27/4                   0.81
  Body surface area (m^2^)            1.93±0.20          1.84±0.16           1.96±0.20              0.061
  Diabetes, *n* (%)                   7 (17)             1 (1)               6 (19)                 0.49
  Systemic hypertension, *n* (%)      15 (37)            2 (20)              13 (42)                0.21
  Hypercholesterolemia, *n* (%)       10 (24)            0                   10 (32)                0.039
  Smoke, *n* (%)                      26 (63)            6 (60)              20 (65)                0.80
  CV family history, *n* (%)          14 (34)            3 (30)              11 (35)                0.75
  Culprit coronary artery, *n* (%)                                                                  
   LAD                                25 (61)            6 (60)              19 (61)                0.94
   RCA                                11 (27)            2 (20)              9 (29)                 0.58
   LCx                                5 (12)             2 (20)              3 (10)                 0.39
  Number of vessel disease, *n* (%)                                                                 
   1-vessel disease                   34 (83)            8 (80)              26 (84)                0.78
   2-vessel disease                   6 (15)             2 (20)              4 (13)                 0.58
   3-vessel disease                   1 (2)              0                   1 (3)                  0.57
  ACE-Is/ARBs, *n* (%)                36 (88)            8 (80)              28 (90)                0.58
  Beta-blockers, *n* (%)              38 (93)            9 (90)              29 (94)                1.000
  Calcium channel blockers, *n* (%)   2 (5)              0                   2 (6)                  1.000
  Diuretics *n* (%)                   3 (7)              1 (10)              2 (6)                  1.000

ACE-Is=Angiotensin converting enzyme inhibitors, ARBs=Angiotensin receptor blockers, CV=Cardiovascular, LAD=Left anterior descending, LCx=Left circumflex, LVR=Left ventricular remodeling, RCA=Right coronary artery

Cardiac magnetic resonance imaging {#sec2-2}
----------------------------------

All images were acquired using a 1.5-T CMR imaging system (Signa HDX, GE Medical Systems, Milwaukee, Wisconsin). An 8-channel phased-array surface coil was used. Localization was performed using breath-hold single-phase steady-state-free precession (SSFP) images of true anatomical axes of the heart. Subsequently, cine SSFP and delayed enhancement (DE) sequences were obtained. Cine SSFP images were acquired in short- and long-axis views. For the short-axis view sequences, a slice thickness of 10 mm with no gap in identical slice positions, covering the LV from the base to apex, was used. The DE images (fast-gradient-echo inversion-recovery) were acquired 7--10 min after bolus intravenous injection of 0.15 mmol/kg body weight of gadolinium-diethylenetriamine penta-acetic acid (gadobutrol, Schering, Germany), followed by saline flush. The inversion time was adapted individually to null normal myocardium. LV EDV, ESV, stroke volume (SV), mass, and EF were calculated according to standard methods. The LV-SV was calculated as LV-EDV − LV-ESV. The LV global volume was defined as the sum of the LV mean cavity volume (\[LV-EDV + LV-ESV\]/2) and the myocardium volume. LV myocardial volume was calculated as LV myocardial mass divided by the specific myocardial density (1.05 g/mL). The LV-GFI was defined according to the following established formula and expressed as a percentage: LV-GFI = (LV-SV/LV global volume) × 100.\[[@ref8]\] For myocardial DE and edema analysis, CMR images were analyzed using the software Segment CMR (Medviso, Lund, Sweden).\[[@ref9]\] Myocardial edema imaging was performed with the use of breath-hold black-blood T2-weighted, short-tau inversion recovery (T2w-STIR) time, fast spin-echo imaging in cardiac short-axis orientation. Salvaged myocardium was quantified as the difference between the area of increased T2w-STIR signal (area at risk) and the area of late gadolinium enhancement. Myocardial salvage index (MSI, in %) was calculated by normalizing salvaged myocardium for the area at risk as previously described.\[[@ref10][@ref11]\] The MVO was assessed approximately 15 min after gadolinium injection, again using DE images. It was defined as a dark zone within the infarcted segments, usually located in the subendocardium, and expressed in % of the LV myocardial volume.\[[@ref11]\]

Conventional and speckle-tracking echocardiography {#sec2-3}
--------------------------------------------------

In all patients, a comprehensive transthoracic echocardiography examination was performed using commercially available ultrasound systems (Vivid 7 and E9, GE Medical Systems, Milwaukee, WI, USA) equipped with a 3.5 MHz phased-array transducer. Image and Doppler acquisitions were obtained at held end-expiration. LV-EF was calculated using the Simpson\'s biplane method.\[[@ref12]\] For the 2D-STE image acquisition, sector size and depth were adjusted to achieve optimal visualization of all LV myocardium in the 3 standard apical views (4-, 2-, and long-axis view) with a frame rate between 60 and 100 fps. The LV longitudinal myocardial strain was assessed using a commercially available software (EchoPAC PC 112 rev. 1.3, GE Medical Systems, Milwaukee, WI, USA). End-systole was defined by the aortic valve closure in the apical long-axis view. The regions of interest were manually outlined at end-systole by marking the endocardial borders in the apical views. A manual adjustment was performed if the automated tracking was suboptimal. Peak systolic longitudinal myocardial strain was automatically calculated throughout the myocardium for each LV apical view and reported spatially - from base to apex and circumferentially - in a polar plot map using a color-coded parametric representation. The area of SAS was contoured and expressed as a percentage of the total myocardial area as described in a previous investigation.\[[@ref7]\] The GLS was determined by averaging all peak systolic segmental strain values from the 3 standard apical views. Longitudinal peak strain values were averaged over 2 consecutive cardiac cycles.

Study end-point {#sec2-4}
---------------

LVR was defined as a 15% increase in LV-EDV evaluated by CMR after 6 months from the baseline value.\[[@ref13]\]

Statistical analysis {#sec2-5}
--------------------

Continuous variables were expressed as average values ± standard deviation, whereas categorical variables were expressed as percentages. Baseline and 6-month values were compared using the Student\'s *t*-test. Values of the subgroups of patients with and without LVR were compared using the Student\'s *t*-test or the Chi-square test when indicated. The following variables were included in the predictive analysis: Echocardiographic LV-EF, GLS, SAS area, and CMR LV-GFI, MSI, and MVO. The association between all variables and LVR was assessed first using the Pearson\'s *r* correlation coefficient (univariable analysis). Subsequently, a stepwise multivariable regression analysis was applied. The receiver-operating characteristic (ROC) curve analysis was performed to select optimal cutoff value for the variable which remained predictive at the multivariable analysis, calculating the area under the ROC curve (AUC) with the 95% confidence intervals (CIs). The statistical analysis was performed using MedCalc Statistical Software version 11.2.1.0. *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Overall patients {#sec2-6}
----------------

Forty-one consecutive patients were studied at baseline and after 6 months. CMR parameters describing LV size and systolic function are reported in [Table 2](#T2){ref-type="table"}. Baseline values of parameters tested for the prediction of LVR are reported in [Table 3](#T3){ref-type="table"}. MVO was seen in 22 patients (54%).

###### 

Cardiac magnetic resonance parameters evaluated at baseline and after 6 months

             Overall patients   *P*\*        Patients with LVR   *P*\*        Patients without LVR   *P*\*     *P*\*\*                                       
  ---------- ------------------ ------------ ------------------- ------------ ---------------------- --------- ------------ ------------ --------- --------- ---------
  EDV (mL)   152.5±34.5         160.1±44.4   0.063               145.1±29.3   185.9±49.8             \<0.001   154.9±36.2   151.8±39.9   0.216     0.442     0.033
  ESV (mL)   83.5±28.0          84.0±38.6    0.876               90.6±26.4    114.7±44.3             0.011     81.2±28.5    74.0±31.3    0.001     0.363     0.003
  SV (mL)    70.1±15.6          76.2±14.0    \<0.001             58.9±15.6    71.2±10.7              0.013     73.8±13.9    77.8±14.7    0.012     0.007     0.197
  EF (%)     46.1±8.8           49.4±9.7     \<0.001             38.4±6.9     39.9±7.5               0.425     48.6±8.0     52.5±8.2     \<0.001   \<0.001   \<0.001

\*Baseline versus 6-month evaluation, \*\*Patients with versus without LVR at baseline and 6 months. EDV=End-diastolic volume, ESV=End-systolic volume, SV=Stroke volume, EF=Ejection fraction, LVR=Left ventricular remodeling

###### 

Cardiac magnetic resonance and echocardiographic parameters tested for left ventricular remodeling prediction

                         Overall patients (*n*=41)   Patients with LVR (*n*=10)   Patients without LVR (*n*=31)   *P*
  ---------------------- --------------------------- ---------------------------- ------------------------------- ---------
  CMR                                                                                                             
   GFI (%)               28.7±6.2                    23.3±3.9                     30.5±5.9                        0.003
   MSI (%)               42±29                       35.8±17.3                    44.6±32.4                       0.419
   MVO (%)^§^            1.99±2.20                   3.0±2.1                      1.29±2.1                        0.069
  Echocardiography (%)                                                                                            
   EF                    47.3±9.3                    39.7±7.6                     49.8±8.5                        0.002
   GLS                   −13.9±3.4                   −11.2±2.5                    −14.8±3.2                       0.003
   SAS area              10.4±9.7                    22.3±8.9                     6.6±6.4                         \<0.001

^§^In 22 patients at baseline, 9 with LVR and 13 without LVR. GFI=Global function index, MSI=Myocardial salvage index, MVO=Microvascular obstruction, EF=Ejection fraction, GLS=Global longitudinal strain, SAS=Severe altered longitudinal strain, LVR=Left ventricular remodeling, CMR=Cardiac magnetic resonance

Left ventricular remodeling {#sec2-7}
---------------------------

According to the 6-month CMR LV-EDV variation, 10 patients (24%) showed LVR and 31 did not (76%) \[[Table 1](#T1){ref-type="table"}\]. No differences between patients with and without LVR were observed in terms of age, gender ratio, body surface area, cardiovascular risk factors, culprit coronary artery, and number of vessel disease \[[Table 1](#T1){ref-type="table"}\].

At baseline, LVR patients had a lower LV-EF, LV-GFI, GLS, and a higher MVO and SAS area \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\]. No significant differences were observed in terms of LV volumes and MSI \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\] although there was a trend for lower LV-EDV and higher LV-ESV mean values for LVR patients \[[Table 2](#T2){ref-type="table"}\].

Prediction of left ventricular remodeling {#sec2-8}
-----------------------------------------

At the univariable analysis, a significant correlation was found between the 6-month LV-EDV variation and baseline SAS area \[*r* = 0.81, *P* \< 0.001; [Figure 1](#F1){ref-type="fig"}\], LV-GFI (*r* = −0.56, *P* \< 0.001), MVO (*r* = 0.55, *P* \< 0.001), LV-EF (*r* = −0.42, *P* = 0.006), and GLS (*r* = 0.42, *P* = 0.007), whereas MSI did not show a significant correlation (*r* = −0.25, *P* = 0.113). At the multivariable analysis, a significant correlation remained only for the SAS area (*r* = 0.80, *P* \< 0.001). The ROC curve analysis showed that a baseline SAS area ≥15% predicted LVR at 6 months with a sensitivity and a specificity of 80.0% and 90.3%, respectively \[AUC 0.934, 95% CIs 0.810--0.988, *P* \< 0.001; [Figure 2](#F2){ref-type="fig"}\].

![LV-SAS=Left ventricular severely altered longitudinal systolic area, LV-EDV=Left ventricular end-diastolic volume](JCE-27-93-g001){#F1}

![LV-SAS=Left ventricular severely altered longitudinal systolic area, LVR=Left ventricular remodeling, AUC=Area under the curve, CIs=Confidence intervals](JCE-27-93-g002){#F2}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Our data show that early evaluation of the 2D-STE SAS area after STEMI can be used to predict LVR. Assessment of other echocardiographic and CMR indices seems not to be predictive as the use of the SAS area.

Importance of predicting left ventricular remodeling {#sec2-9}
----------------------------------------------------

LVR is a major predictor of morbidity and mortality in overt congestive heart failure.\[[@ref14]\] Morphologically, LVR following acute MI is characterized by chamber dilation, thinning of the infarcted segments, and compensatory hypertrophy in the noninfarcted myocardium. It is considered as an adaptive progressive process contributing to maintenance of the LV systolic function. However, this occurs only in some STEMI patients while others remain relatively stable without a significant LV cavity dilation.\[[@ref15]\] Since LVR has been associated with the development of heart failure and a poor survival rate, its early identification is of clinical importance\[[@ref16]\] to set up appropriate preventive strategies, especially for the high-risk patients.\[[@ref1][@ref17]\]

Echocardiographic predictors {#sec2-10}
----------------------------

Early echocardiographic evaluation of LV-EF is generally performed after an acute MI to assess the degree of myocardial damage and as a marker of early and late complications.\[[@ref16]\] However, early assessment of LV-EF in this setting can be misleading\[[@ref18]\] because it is affected by the presence of myocardial stunning, thus it may not distinguish viable from nonviable myocardium.\[[@ref13][@ref19]\]

Various studies suggested an additive value of deformation imaging parameters, and particularly of GLS, in predicting LVR. D'Andrea *et al*.\[[@ref13]\] found that GLS evaluated in patients with non-ST elevated MI is a reliable predictor of LVR (defined as a ≥15% increase in LV-EDV 6 months after the acute MI) with a sensitivity of 84.8% and specificity of 87.8%. Zaliaduonyte-Peksiene *et al*.\[[@ref20]\] confirmed the role of GLS in predicting LVR following acute MI (defined as a ≥15% increase in LV-EDV at the 4-month follow-up evaluation). Antoni *et al*.\[[@ref21]\] reported that GLS has a strong prognostic value in terms of all-cause mortality, reinfarction, hospitalization due to heart failure, or revascularization in patients after acute MI.

Our group\[[@ref7]\] has recently shown that the SAS area obtained acutely from 2D-STE is related to the CMR transmural scar size 6 months after the acute MI. It, therefore, has the potential to predict development of LVR. Indeed, in the present investigation, we found that the SAS area was a very good predictor of LVR and when compared with other indices, it remained the only significant predictor at the multivariable analysis. In particular, among the echocardiographic parameters, both the LV-EF and GLS did not retain their similar predictive value observed at the univariable analysis. While the weakness of the LV-EF as an LVR predictor has been explained above, the failure of GLS to maintain its predictive value at the multivariable analysis needs to be clarified. In our opinion, this mainly relies on the functional information carried by GLS, which takes into account the contribution of all myocardial segments to LV contraction, that is, it includes both normally and abnormally contracting regions. Conversely, the size of the SAS area is primarily an expression of the severely dysfunctioning nonviable myocardium.\[[@ref7]\]

Cardiac magnetic resonance predictors {#sec2-11}
-------------------------------------

In our study, we have tested a number of CMR predictors of LVR. LV-GFI is a novel index that integrates information about LV myocardial structure and global systolic function.\[[@ref8]\] Eitel *et al*.\[[@ref6]\] recently reported that the LV-GFI strongly correlates with markers of severe myocardial and microvascular damage in patients with STEMI, offering prognostic information beyond traditional cardiac risk factors including the LV-EF. Other CMR indices, such as MVO and MSI, have also been reported to have a prognostic value in acute reperfused STEMI. For example, de Waha *et al*.\[[@ref22]\] showed that MSI is a stronger predictor for adverse clinical outcome in comparison to other CMR parameters, such as MVO and infarct size. In addition, Bodi *et al*.\[[@ref23]\] reported that that an MVO \>2.5% can predict LVR after acute MI.

In our patients, we found significant correlations between baseline LV-GFI and MVO with LVR at the univariable analysis, whereas MSI did not correlate significantly. However, at the multivariable analysis, none of these CMR parameters was associated with LVR. We did not find a single explanation for the different predictive value of the CMR indices observed in our study and in the literature. However, there are several factors that may have played a role. First, although the LV-GFI carries additional information to LV-EF by accounting for LV mass and hypertrophy, in acute STEMI patients, it cannot be determined if such LV "hypertrophy" was related to previous long-standing arterial hypertension (true LV hypertrophy) or by acute changes induced by myocardial edema as a consequence of the ischemic event itself.\[[@ref24]\] In this latter case, the prognostic impact of the LV-GFI could be different. Second, it is well known that, in the acute phase of MI, late-enhancement images may overestimate acute MI size by including the edematous border surrounding the infarct (peri-infarct zone): this could significantly affect the estimate of the MSI.\[[@ref22]\] Third, as far as the MVO is concerned, in our patient population, the MVO evaluation was possible only in 54% of patients. In addition, questions have been raised regarding physiological and mechanistic assumptions underlying the T2-weighted CMR approaches for assessing the myocardium at risk.\[[@ref25][@ref26]\] Therefore, CMR data regarding the area at risk and myocardial salvage should be considered cautiously, as also pointed out by other authors.\[[@ref6]\]

Study limitations {#sec2-12}
-----------------

In this retrospective investigation, a limited number of STEMI patients was evaluated due to the need for a CMR performed both early and after 6 months from STEMI. However, despite this limitation, we could clearly demonstrate that the early evaluation of the SAS area size is a predictor of LVR. We recognize that there are many ways to define LVR and that results may change according to the LVR definition. However, the LVR definition applied in our investigation (that is, the LV-EDV variation) has been used in previous studies\[[@ref3][@ref13][@ref20]\] and has the advantage to be clinically applicable. We recognize that the follow-up duration of our study is limited and that a longer follow-up would be necessary to confirm our results. This might be planned in a future prospective investigation. Global circumferential strain was not investigated in this study. Other authors, however, showed that this parameter may better explore the transmurality of the LV damage after STEMI and is a predictor of LVR.\[[@ref27][@ref28]\] Compared to strain, strain rate seems to be less load dependent, maybe better measure of contractility, and theoretically, more sensitive than strain to myocardial pathology.\[[@ref29][@ref30]\] Some authors showed that both longitudinal and circumferential strain rate were independent predictors of outcome after MI, whereas only circumferential strain rate was predictive of LV remodeling.\[[@ref31]\] A certain spatial distortion occurs in representing the LV apical segments in the polar plot format, so some underestimation of the size of the SAS area may be expected at the apex.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

Early evaluation of the SAS area by 2D-STE significantly predicts LVR 6 months after a STEMI. Further investigations are needed to verify the impact of this evaluation in predicting patients' survival.
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